Endoscopic Submucosal Dissection Market - By Product (Knives, Gastroscopes & Colonoscopes, Injection Agents, Graspers/Clips, Tissue Retractors), By Application (Stomach, Colon, Esophageal), By End-use (Hospitals, ASCs)

Description

List of Tables

Endoscopic Submucosal Dissection Market size is estimated to expand at 6.3% CAGR from 2023-2032, driven by the increasing prevalence of gastric cancer globally. Of late, several nations, particularly in Asia and America are recording elevated rates of gastric cancer prevalence, further driving the demand for endoscopic submucosal dissection (ESD) as a vital treatment modality. According to the American Cancer Society's estimates for 2022, stomach cancer accounts for 1.5% of all new cases in the U.S. each year. ESD has also emerged as a highly preferred treatment option given its ability to precisely target and eliminate early-stage gastric tumors while preserving organ function.

Moreover, the introduction of innovative endoscopic tools with better imaging capabilities, and precision instruments with enhanced effectiveness and safety of ESD procedures will contribute to the market expansion. For instance, in January 2023, FUJIFILM India, announced the launch of ClutchCutter and FushKnife to assist aid clinicians in performing effective endoscopic submucosal dissection interventions within the digestive tract.

The endoscopic submucosal dissection industry is segmented into product, application, end-use, and region.

Based on product, the market share from the gastroscopes and colonoscopes segment is expected to attain 6.2% CAGR from 2023-2032. Gastroscopes and colonoscope devices are recording high demand to perform minimally invasive procedures for gastrointestinal disorders as they provide high-resolution imaging and precise control during ESD procedures for better diagnostic and therapeutic outcomes. Furthermore, the increasing emphasis on early detection and intervention by healthcare systems globally will propel the segment growth.

As per application, the endoscopic submucosal dissection industry from the esophageal cancer segment is estimated to depict 5.9% CAGR through 2032. ESD procedures for esophageal lesions and early-stage cancers have become increasingly prevalent due to their minimally invasive nature and the ability to preserve organ function. The widespread awareness of esophageal disorders and improving diagnostic capabilities is also surging the demand for sophisticated endoscopic tools tailored for esophageal applications.

Regionally, the Asia Pacific endoscopic submucosal dissection industry is poised to exhibit 7.2% growth rate between 2023 and 2032 owing to the rising prevalence of gastrointestinal diseases coupled with the growing focus on minimally invasive procedures. Countries, such as Japan and South Korea are working on establishing ESD practices due to the high incidence of gastric cancer. Moreover, the growing advancements in healthcare infrastructure, increasing patient awareness, and the rising aging population will augment the industry outlook.

Product Code: 7139

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & working
1.3 Data collection
1.4 Base estimates & workings
1.5 Forecast calculations
1.6 Data Sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Global endoscopic submucosal dissection market 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Product trends
- 2.1.4 Application trends
- 2.1.5 End-use trends

Chapter 3 Endoscopic Submucosal Dissection Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence of gastrointestinal diseases
  - 3.2.1.2 Growing geriatric population
  - 3.2.1.3 Increasing advancements in endoscopic technologies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of equipment and procedure
  - 3.2.2.2 Limited availability of skilled endoscopists
3.3 Growth potential analysis
- 3.3.1 By product
- 3.3.2 By application
- 3.3.3 By end-use
3.4 COVID- 19 impact analysis
3.5 Technology landscape
3.6 Regulatory landscape
3.7 Supply chain analysis
3.8 Gap analysis
3.9 Porter's analysis
3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategy dashboard, 2022

Chapter 5 Endoscopic Submucosal Dissection Market Size and Forecast, By Product, 2018-2032 (USD Million)

5.1 Key trends, by product
5.2 Knives
5.3 Gastroscopes & colonoscopes
5.4 Injection agents
5.5 Graspers/clips
5.6 Tissue retractors
5.7 Other products

Chapter 6 Endoscopic Submucosal Dissection Market Size and Forecast, By Application, 2018-2032 (USD Million)

6.1 Key trends, by application
6.2 Stomach cancer
6.3 Colon cancer
6.4 Esophageal cancer

Chapter 7 Endoscopic Submucosal Dissection Market Size and Forecast, By End-use, 2018-2032 (USD Million)

7.1 Key trends, by end-use
7.2 Hospitals
7.3 Specialty clinics
7.4 Ambulatory surgical centers

Chapter 8 Endoscopic Submucosal Dissection Market Size and Forecast, By Region, 2018-2032 (USD Million)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East & Africa

Chapter 9 Company Profiles

9.1 Ovesco Endoscopy AG
9.2 Micro-Tech Endoscopy
9.3 KARL STORZ SE & Co. KG
9.4 Zeon Medical Inc.
9.5 Cook Medical
9.6 Leo Medical Co.,Ltd.
9.7 Boston Scientific Corporation
9.8 FUJIFILM Holdings Corporation
9.9 Beijing ZKSK Technology Co., Ltd.
9.10 Hangzhou AGS Medical Technology Co., Ltd
9.11 Olympus Corporation
9.12 Creo Medical PLC